TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
ZBIO

Zenas BioPharma, Inc.

Healthcare · Biotechnology

28.40$ -1.3% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Zenas BioPharma, Inc. (ZBIO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 69.1% of the shares are freely tradable; institutional investors hold 90.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 90.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 23.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 69.1%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 26.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 65Mio.

Largest Shareholders

Institutions

Institutions ZBIO
Name Stake (%) Shares Change (%) Date
FMR Inc 14.59 9,506,701 +4.7 06/30/2026
SR ONE CAPITAL MANAGEMENT, LP 7.73 5,037,854 +0.0 06/30/2026
NEA Management Company, LLC 6.17 4,023,219 +0.0 06/30/2026
Enavate Sciences GP, LLC 6.01 3,919,159 +0.0 06/30/2026
Federated Hermes Inc 4.78 3,116,805 -0.3 06/30/2026
BlackRock Inc 4.12 2,686,225 +31.8 06/30/2026
Capital Research & Mgmt Co - Division 3 3.84 2,502,912 +2.8 06/30/2026
Polar Capital Holdings PLC 3.70 2,412,772 -5.3 06/30/2026
Royalty Pharma Sub-Manager, LLC 3.66 2,388,150 +0.0 06/30/2026

Funds

Funds ZBIO
Name Stake (%) Shares Change (%) Date
American Funds SMALLCAP World A 4.37 2,849,198 +17.1 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?